Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reliant, GlaxoSmithKline deal

GSK will acquire Reliant for $1.7 billion in cash. The acquisition gives GSK U.S. rights to Lovaza omega 3 acid ethyl esters, which is

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE